Shanghai Fudan Forward S&T Co., Ltd Class A

Shanghai Fudan Forward S&T Co., Ltd Class A

SSSE:600624
4.50
CNY
+0.03
(+0.67%)
-0.30EPS
3.15BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.58
1.97
1.36
0.99
1.07
1.46
2.06
1.37
1.52
1.15
1
0.94
0.94
0.92
Basic EPS, GAAP
-0.01
0.01
0.1
0.06
0.06
0.05
0.01
-0.09
-0.15
-0.01
-0.03
-0.19
-0.29
-0.29
Free Cash Flow per Basic Share
-0.44
-0.18
-0.04
-0.11
0.1
0.16
0.01
0.06
0.03
0.01
- -
-0.03
-0.08
- -
Dividend per Share
0.08
0.1
0.07
0.06
0.06
0.05
0.05
0.05
0.03
0.03
0.03
0.02
0.02
0.02
Book Value per Share
0.95
1.39
1.45
1.49
1.52
1.55
1.53
1.41
1.23
1.17
1.13
0.93
0.64
0.63
Tangible Book Value per Share
0.83
1.29
1.34
1.37
1.41
1.44
1.42
1.3
1.12
1.07
1.02
0.81
0.52
0.5
Basic Weighted Avg Shares
604
513
528
681
686
689
678
687
687
689
683
683
681
679
Sales/Revenue/Turnover
952
1,008
718
671
736
1,008
1,400
940
1,041
789
680
645
640
623
Operating Margin (%)
8.23
5.78
8.03
7.56
8.05
6.13
3.61
7.82
8.51
3.27
0.5
-4.93
-6.78
-6.86
Depreciation Expense
17
18
18
26
26
25
25
25
38
38
55
52
50
- -
Net Income, GAAP
-4
6
52
38
40
36
5
-60
-106
-6
-22
-133
-198
-198
Effective Tax Rate (%)
87.01
41.16
22.47
45.92
28.26
26.59
68.74
- -
- -
280.73
- -
- -
- -
- -
Profit Margin (%)
-0.45
0.55
7.28
5.68
5.5
3.62
0.34
-6.35
-10.22
-0.79
-3.22
-20.64
-30.86
-31.72
Working Capital
67
373
277
348
358
359
365
350
320
430
252
139
-42
-37
LT Debt
44
94
111
65
44
- -
- -
38
50
142
26
16
6
4
Total Equity
616
1,013
1,057
1,086
1,117
1,138
1,130
1,045
923
915
818
678
474
461
Return on Invested Capital (%)
0.42
1.84
2.97
1.58
2.4
2.7
0.08
- -
- -
-0.43
- -
- -
- -
- -
Return on Capital (%)
-0.47
1.06
3.49
2.58
2.51
2.23
0.34
- -
- -
-3.46
- -
- -
- -
- -
Return on Common Equity (%)
-0.76
0.73
5.38
3.8
3.93
3.47
0.45
-5.92
-11.78
-0.75
-2.77
-18.84
-36.73
-37.2

Capital Structure

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
ST Debt
450
504
477
LT Borrowings
- -
- -
- -
LT Finance Leases
10
6
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
679
679
679
Market Capitalization
4,803
3,594
3,152

Working Capital

CNY

•

in mil. unless spec.
Jun'25
Dec'25
Mar'26
Total Current Assets
834
703
658
Cash, Cash Equivalents & STI
209
192
146
Accounts Receivable, Net
70
71
68
Inventories
508
397
390
Total Current Liabilities
692
745
696
Payables & Accruals
- -
- -
- -
ST Debt
450
504
477
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-7.11%
-14.07%
-30.05%
Free Cash Flow
457.12%
779.75%
180.88%
Net Income, GAAP
-68.18%
158.84%
48.3%
Sales/Revenue/Turnover
1.3%
-6.64%
-0.81%
Total Cash Common Dividend
-9.42%
-18.51%
-11.64%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
155
164
157
169
645
2025
161
165
- -
147
640
2026
149
- -
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.01
-0.02
-0.15
-0.19
2025
-0.01
- -
- -
-0.26
-0.29
2026
-0.02
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
0.01
0.02
2025
- -
- -
- -
- -
0.02
2026
0.01
- -
- -
- -
- -

Company Description

CEO
Zheng Song
Full Time Employees
1,355
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Room 107, Building 2 Shanghai SH China 200433
IPO Date
Jan 5, 1993
Business
Shanghai Fudan Forward S&T Co., Ltd (600624.SS), also known as Shanghai Fudan Fuhua Technology Co., Ltd, engages primarily in the research, development, production, and sale of pharmaceuticals alongside software development and high-tech park operations. The company operates three core business segments: biomedicine, featuring chemical drugs, Chinese patent medicines, freeze-dried powder injections, and solid preparations including digestive system drugs such as injectable glutathione and isosorbide nitrate tablets; nervous system drugs such as carbamazepine tablets and neuroleptic tablets; antineoplastic drugs such as flutamine tablets and tamoxifen citrate tablets; circulatory system drugs such as shuangyipine and triptolioid tablets; and immune regulation drugs; digital economy, centered on financial insurance system software products exported to Japan through subsidiary Shanghai Zhonghe Software Co., Ltd; and high-tech parks, encompassing self-owned housing leasing, real estate development, investment promotion, consulting, and property management services. Founded in 1984 as Fudan University Science and Technology Development Company and listed on the Shanghai Stock Exchange in 1993, the company is headquartered in Shanghai, China, with primary operations in the domestic market and software exports to Japan; it employs over 1,400 people across 28 subsidiaries. Recent developments include a major share transfer in November 2025, whereby controlling shareholder Fudan University transferred shares to Fuxin Fangao and Guosheng Investment under a Share Transfer Framework Agreement, prompting stock price fluctuations and potential ownership changes; additionally, the company reported improved half-year net profits in 2025 driven by subsidiaries Shanghai Zhonghe Software and Shanghai Fuhua High-Tech Park Development, alongside completion of industrial and commercial registrations for wholly-owned subsidiaries and board resolutions on strategic matters.